Yazar "Bulbul, Ece Ozcan" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim Yok
    Öğe
    Delivering active molecules to the eye; the concept of electrospinning as potent tool for drug delivery systems
    (Elsevier, 2023) Siafaka, Panoraia I.; Bulbul, Ece Ozcan; Miliotou, Androulla N.; Karantas, Ioannis D.; Okur, Mehmet Evren; Okur, Neslihan Ustundag
    Ocular drug delivery is a challenging but fascinating topical route of administration. Although the eye is easily accessible to common drug formulations such as drops, its complex structure presents main obstacles to successfully deliver drugs. Low ocular bioavailability due to pre-corneal fluid and gravity drainage limits the efficacy of the products. Therefore, researchers have proposed various drug delivery systems synthesized by biomaterials, mostly polymers, which can deliver active ingredients to the ocular surface and remain for longer period. Such systems as electrospun fibrous structures resembling the extracellular matrix can embed various therapeutic molecules aiming to target eye diseases. The electrospun matrices, which can be used as inserts or implants, offer biocompatibility, biodegradability, and good mechanical properties. At the same time, they can be molded into different shapes and textures, significant features for ocular delivery. Over the last decades, the electrospinning process has offered many advancements in tissue engineering and drug delivery fields; however, the clinical translation of the electrospun fibrous matrices is still in the embryonic stages. This review article focuses on the recent therapeutic applications of ocular fibrous systems as potent drug delivery tools. In addition, authors have categorized the electrospun matrices according to the target eye disease, such as glaucoma, ocular infections, and other eye diseases.
  • Küçük Resim Yok
    Öğe
    Nano-based carriers for pulmonary drug delivery: A review on the available drug delivery applications and toxicity issues
    (Elsevier, 2024) Siafaka, Panoraia I.; Bulbul, Ece Ozcan; Miliotou, Androulla N.; Karantas, Ioannis D.; Okur, Mehmet Evren; Okur, Neslihan Ustundag
    In the last decade, nanocarriers have been widely used to target specific organs and disorders of any kind. Nonetheless, the commercialization of nanocarriers for many disorders have not been finalized; toxicity matters, materials which have not granted approval by regular authorities, or unavailability of clinical studies are some of the issues which the researchers should overcome to force the marketing of nanoparticles. Pulmonary diseases affect million people worldwide, in example, pulmonary infections, malignancies, asthma and chronic obstructive pulmonary disease are among the most frequent. It has been reported that the local administration of drugs to lungs via inhalers can solve the most side effects arouse by per os or intravenous delivery. Therefore, in this review the current state of drug delivery nanosized carriers which can be applied via inhalation are discussed and analyzed. Moreover, the possible toxicity issues due to their small size or materials used for the preparation of such nanocarriers are being discussed. It was performed a thorough literature research based on databases as PubMed (R) and ScienceDirect (R) by using nanocarriers, pulmonary, lung disorders, inhalation, toxicity as keywords. According to our inclusion criteria, studies including the previous terms, focusing on nanoparticles that can be applied for lung disorders management, were added. From our point of view, this bibliographic analysis can enhance the present knowledge of researchers for inhalable nanostructures, targeting pulmonary diseases.
  • Küçük Resim Yok
    Öğe
    A paradigm use of monoclonal antibodies-conjugated nanoparticles in breast cancer treatment: current status and potential approaches
    (Taylor & Francis Ltd, 2024) Al-Taie, Anmar; Bulbul, Ece Ozcan
    Monoclonal antibodies (mAbs) are integral to cancer treatment over conventional non-specific therapy methods. This study provides a scoping review of the clinically approved mAbs, focusing on the current application of different nanocarrier technologies as drug delivery targets for mAb-conjugated nanoparticles (NPs) as potential features for breast cancer (BC) treatment. An extensive literature search was conducted between the years 2000 and 2023 using various sources of databases. The first part covered mAb classification, types, and mechanisms of action, pharmacokinetics and clinical applications in BC. The second part covered polymeric, lipid and inorganic-based NPs, which are a variety of mAb-conjugated NPs targeting BC. A total of 20 relevant studies were enrolled indicating there are three different types of nanoparticular systems (polymeric NPs, inorganic NPs and lipid-based NPs) that can be used for BC treatment by being loaded with various active substances and conjugated with these antibodies. While mAbs have altered the way in cancer treatment due to targeting cancer cells specifically, the delivery of mAbs with nanoparticulate systems is important in the treatment of BC, as NPs are still being investigated as distinctive and promising drug delivery methods that can be employed for effective treatment of BC.